Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn's Disease: Is There Any Difference between Small Intestine and Colonic Lesions?

被引:3
|
作者
Matsumoto, Satohiro [1 ]
Mashima, Hirosato [1 ]
机构
[1] Jichi Med Univ, Dept Gastroenterol, Saitama Med Ctr, 1-847 Amanuma, Saitama, Saitama 3308503, Japan
关键词
leucine-rich alpha-2 glycoprotein; cutoff value; delta value; mucosal healing; small intestine; Crohn's disease; INFLAMMATORY BOWEL DISEASES; FECAL CALPROTECTIN; ENDOSCOPIC ACTIVITY; MAGNETIC-RESONANCE; BIOMARKER; LACTOFERRIN; MARKER; SCORE; CRP;
D O I
10.1093/crocol/otad028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary The superiority of leucine-rich alpha 2 glycoprotein (LRG) to C-reactive protein (CRP) differs between small intestinal and colonic lesions. For Crohn's disease patients with ileum-dominant activity, monitoring of both LRG and CRP is necessary, instead of monitoring CRP alone. Background The usefulness of leucine-rich alpha 2 glycoprotein (LRG) to evaluate Crohn's disease (CD) activity differs among various intestinal lesions. We aimed to evaluate the association between endoscopic disease activity based on the Simple Endoscopic Score for Crohn's disease (SES-CD) and LRG level separately for small intestinal and colonic lesions. Methods We examined the correlation between LRG level and SES-CD and performed receiver operating characteristic (ROC) analysis to determine the LRG cutoff value in 141 patients who underwent endoscopy (total 235 measurements). Furthermore, the LRG cutoff value was analyzed by comparing small intestinal and colonic lesions. Results LRG levels were significantly higher in patients without mucosal healing than in those with mucosal healing (15.9 mu g/mL vs 10.5 mu g/mL, P < .0001). The LRG cutoff value for mucosal healing was 14.3 mu g/mL (area under the ROC curve [AUC]: 0.80; sensitivity: 0.89; specificity: 0.63). The LRG cutoff value for patients with type L1 was 14.3 mu g/mL (sensitivity: 0.91; specificity: 0.53), and that for patients with type L2 was 14.0 mu g/mL (sensitivity: 0.95; specificity: 0.73). The diagnostic performance (AUC) of LRG and C-reactive protein (CRP) for mucosal healing was, respectively, 0.75 and 0.60 (P = 0.01) in patients with type L1 and 0.80 and 0.85 (P = 0.90) in patients with type L2. Conclusions The optimal LRG cutoff value for evaluating mucosal healing in CD is 14.3 mu g/mL. LRG is more useful than CRP for predicting mucosal healing in patients with type L1. The superiority of LRG to CRP differs between small intestinal and colonic lesions.
引用
收藏
页数:8
相关论文
共 42 条
  • [31] Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease
    Ha, Y-J
    Kang, E-J
    Lee, S-W
    Park, Y-B
    Lee, S-K
    Song, J-S
    Choi, S. T.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2015, 44 (05) : 399 - 403
  • [32] Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study
    Shinichiro Shinzaki
    Katsuyoshi Matsuoka
    Hiroki Tanaka
    Fuminao Takeshima
    Shingo Kato
    Takehiro Torisu
    Yuki Ohta
    Kenji Watanabe
    Shiro Nakamura
    Naoki Yoshimura
    Taku Kobayashi
    Akiko Shiotani
    Fumihito Hirai
    Sakiko Hiraoka
    Mamoru Watanabe
    Minoru Matsuura
    Shohei Nishimoto
    Shinta Mizuno
    Hideki Iijima
    Tetsuo Takehara
    Tetsuji Naka
    Takanori Kanai
    Takayuki Matsumoto
    Journal of Gastroenterology, 2021, 56 : 560 - 569
  • [33] Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
    Takahiro Amano
    Takeo Yoshihara
    Shinichiro Shinzaki
    Yuko Sakakibara
    Takuya Yamada
    Naoto Osugi
    Satoshi Hiyama
    Yoko Murayama
    Koji Nagaike
    Hideharu Ogiyama
    Toshio Yamaguchi
    Yuki Arimoto
    Ichizo Kobayashi
    Shoichiro Kawai
    Satoshi Egawa
    Takashi Kizu
    Masato Komori
    Yuri Tsujii
    Akiko Asakura
    Taku Tashiro
    Mizuki Tani
    Yuriko Otake-Kasamoto
    Ryotaro Uema
    Minoru Kato
    Yoshiki Tsujii
    Takahiro Inoue
    Tomomi Yamada
    Tetsuhisa Kitamura
    Atsushi Yonezawa
    Hideki Iijima
    Yoshito Hayashi
    Tetsuo Takehara
    Scientific Reports, 14 (1)
  • [34] Colonic Leucine-Rich Repeat Kinase 2 Expression Is Increased and Associated With Disease Severity in Patients With Parkinson's Disease
    Liao, Peng-Hsiang
    Chiang, Han-Lin
    Shun, Chia-Tung
    Hang, Jen-Fan
    Chiu, Han-Mo
    Wu, Ming-Shiang
    Lin, Chin-Hsien
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 13
  • [35] Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer
    Nambu, Madoka
    Masuda, Takeshi
    Ito, Shingo
    Kato, Ken
    Kojima, Takashi
    Daiko, Hiroyuki
    Ito, Yoshinori
    Honda, Kazufumi
    Ohtsuki, Sumio
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2019, 42 (10) : 1766 - 1771
  • [36] Serum leucine-rich alpha-2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy-naive cases with ulcerative colitis
    Kono, Masashi
    Komeda, Yoriaki
    Tribonias, George
    Yoshida, Saki
    Nomura, Kenji
    Handa, Kohei
    Nagai, Tomoyuki
    Hagiwara, Satoru
    Omoto, Shunsuke
    Takenaka, Mamoru
    Nishida, Naoshi
    Tsuji, Naoko
    Kashida, Hiroshi
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (08): : 579 - 583
  • [37] Serum Leucine-Rich α2 Glycoprotein Could Be a Useful Biomarker to Differentiate Patients with Normal Colonic Mucosa from Those with Inflammatory Bowel Disease or Other Forms of Colitis
    Horiuchi, Ichitaro
    Horiuchi, Kaori
    Horiuchi, Akira
    Umemura, Takeji
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (10)
  • [38] Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker
    Shinozaki, Eiji
    Tanabe, Kazuhiro
    Akiyoshi, Takashi
    Tsuchida, Tomohiro
    Miyazaki, Yuko
    Kojima, Nozomi
    Igarashi, Masahiro
    Ueno, Masashi
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Yamaguchi, Kensei
    Nakayama, Konosuke
    Iijima, Sadayo
    Yamaguchi, Toshiharu
    BMC CANCER, 2018, 18
  • [39] Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study
    Shinzaki, Shinichiro
    Matsuoka, Katsuyoshi
    Tanaka, Hiroki
    Takeshima, Fuminao
    Kato, Shingo
    Torisu, Takehiro
    Ohta, Yuki
    Watanabe, Kenji
    Nakamura, Shiro
    Yoshimura, Naoki
    Kobayashi, Taku
    Shiotani, Akiko
    Hirai, Fumihito
    Hiraoka, Sakiko
    Watanabe, Mamoru
    Matsuura, Minoru
    Nishimoto, Shohei
    Mizuno, Shinta
    Iijima, Hideki
    Takehara, Tetsuo
    Naka, Tetsuji
    Kanai, Takanori
    Matsumoto, Takayuki
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (06) : 560 - 569
  • [40] Combined serum albumin, fecal immunochemical test, and leucine-rich alpha-2 glycoprotein levels for predicting prognosis in remitting patients with ulcerative colitis
    Nakamura, Naohiro
    Honzawa, Yusuke
    Nishimon, Shuhei
    Sano, Yasuki
    Tokutomi, Yutaro
    Ito, Yuka
    Yagi, Naoto
    Kobayashi, Sanshiro
    Aoi, Mamiko
    Tahara, Tomomitsu
    Fukata, Norimasa
    Fukui, Toshiro
    Naganuma, Makoto
    SCIENTIFIC REPORTS, 2023, 13 (01):